Ivonescimab (Anti-PD-1 & VEGF)
Product Specifications
CAS Number
2428381-53-5
Synonyms
AK 112, SMT 112
Target
PD-1/PD-L1
Applications
Apoptosis
Additionnal Information
Ivonescimab is a first-in-class humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A, with immune checkpoint inhibitory, anti-angiogenic, and antineoplastic activities. It is being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors, including breast, liver, and gastric cancers. M.W 201.12 kDa
Storage Conditions
-80°C (avoid freeze-thaw cycles)
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880270-500 1x 500 µL
Fibronectin (HFN7.1), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880525-500 1x 500 µL
CD63 (MX-49.129.5), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470679-100 1x 100 µL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC941478-100 1x 100 µL
CD15 / FUT4 (Reed-Sternberg Cell Marker) (FUT4/1478R), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details